Meloxicam is non-steroidal anti-inflammatory agent and having multiple pharmacological activities have been reported. In the present article involve the development of chitosan nanoparticles of meloxicam and have been subjected to stability test at various pH, drug release study, in vivo pharmacokinetics in wistar rats, and investigated the decreasing the growth of colon cancer cells. Chitosan nanoparticles of meloxicam such as F1 and F2 have shown anticancer activity against HT29 cell lines. Furthermore,. The nanoparticles were in the size range between 170 nm and 220 nm. The oral absorption of nanoparticles were quite higher than the meloxicam alone. Therefore the prepared nanoparticles formulations were showed better activity than meloxicam alone